- Home
- CTNM vs CCIF Comparison
CTNM vs CCIF Comparison
Compare CTNM & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- CCIF
- Stock Information
- Founded
- CTNM 2009
- CCIF 2011
- Country
- CTNM United States
- CCIF United States
- Employees
- CTNM N/A
- CCIF N/A
- Industry
- CTNM
- CCIF Finance/Investors Services
- Sector
- CTNM
- CCIF Finance
- Exchange
- CTNM Nasdaq
- CCIF Nasdaq
- Market Cap
- CTNM 122.9M
- CCIF 113.2M
- IPO Year
- CTNM 2024
- CCIF N/A
- Fundamental
- Price
- CTNM $3.84
- CCIF $6.45
- Analyst Decision
- CTNM Strong Buy
- CCIF
- Analyst Count
- CTNM 4
- CCIF 0
- Target Price
- CTNM $22.50
- CCIF N/A
- AVG Volume (30 Days)
- CTNM 222.5K
- CCIF 76.9K
- Earning Date
- CTNM 08-12-2025
- CCIF 01-01-0001
- Dividend Yield
- CTNM N/A
- CCIF 25.90%
- EPS Growth
- CTNM N/A
- CCIF N/A
- EPS
- CTNM N/A
- CCIF N/A
- Revenue
- CTNM N/A
- CCIF N/A
- Revenue This Year
- CTNM N/A
- CCIF N/A
- Revenue Next Year
- CTNM N/A
- CCIF N/A
- P/E Ratio
- CTNM N/A
- CCIF N/A
- Revenue Growth
- CTNM N/A
- CCIF N/A
- 52 Week Low
- CTNM $3.35
- CCIF $7.43
- 52 Week High
- CTNM $22.00
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- CCIF 52.63
- Support Level
- CTNM N/A
- CCIF $5.91
- Resistance Level
- CTNM N/A
- CCIF $6.14
- Average True Range (ATR)
- CTNM 0.00
- CCIF 0.12
- MACD
- CTNM 0.00
- CCIF 0.03
- Stochastic Oscillator
- CTNM 0.00
- CCIF 83.08
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.